We are live on ! Find out more
MREO

Mereo BioPharma
MREO

64 hedge funds and large institutions have $71.8M invested in Mereo BioPharma in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 12 closing their positions.

New
Increased
Maintained
Reduced
Closed

52% more call options, than puts

Call options by funds: $336K | Put options by funds: $221K

50% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 12

7% more funds holding

Funds holding: 60 → 64 (+4)

3.71% less ownership

Funds ownership: 15.19% → 11.48% (-3.7%)

28% less repeat investments, than reductions

Existing positions increased: 13 | Existing positions reduced: 18

28% less capital invested

Capital invested by funds: $99.6M → $71.8M (-$27.8M)

Holders
64
Holders Change
+4
Holders Change %
+6.67%
% of All Funds
1.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
13
Reduced
18
Closed
12
Calls
$336K
Puts
$221K
Net Calls
+$115K
Net Calls Change
+$35K

Top Buyers

Rank Fund Capital Flow
1
BC
Boxer Capital
California
+$1.74M
2
CC
Clearline Capital
New York
+$1.36M
3
RCMNY
Rubric Capital Management (New York)
New York
+$1.36M
4
OCA
Octagon Capital Advisors
New York
+$775K
5
E
Ergoteles
New York
+$410K

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$5.85M
2
VC
Vivo Capital
California
-$4.25M
3
HA
HHLR Advisors
Cayman Islands
-$3.33M
4
Holocene Advisors
Holocene Advisors
New York
-$2.84M
5
CC
Commodore Capital
New York
-$2.19M
Name Holding Trade Value Shares
Change 		Change in
Stake
RCMNY
1
Rubric Capital Management (New York)
New York
$18.8M +$1.36M +1,756,120 +12%
Point72 Asset Management
2
Point72 Asset Management
Connecticut
$11.2M -$1.13M -1,459,030 -13%
SCM
3
Suvretta Capital Management
New York
$10.2M – – –
RSCM
4
Rock Springs Capital Management
Maryland
$6.98M +$120K +155,332 +3%
CC
5
Clearline Capital
New York
$3.43M +$1.36M +1,756,813 +135%
Citadel Advisors
6
Citadel Advisors
Florida
$3.1M -$886K -1,142,910 -29%
BC
7
Boxer Capital
California
$2.52M +$1.74M +2,250,000 New
Alkeon Capital Management
8
Alkeon Capital Management
New York
$1.94M -$155K -200,000 -10%
TCM
9
Tekla Capital Management
Massachusetts
$1.74M – – –
AG
10
Artal Group
Luxembourg
$1.68M – – –
DCM
11
DAFNA Capital Management
California
$1.23M -$93.1K -120,100 -10%
OCA
12
Octagon Capital Advisors
New York
$1.12M +$775K +1,000,000 New
Goldman Sachs
13
Goldman Sachs
New York
$804K +$1.76K +2,270 +0.3%
SSA
14
Schonfeld Strategic Advisors
New York
$802K -$127K -163,427 -19%
Millennium Management
15
Millennium Management
New York
$786K -$167K -216,162 -24%
BlackRock
16
BlackRock
New York
$757K -$57K -73,569 -10%
Renaissance Technologies
17
Renaissance Technologies
New York
$682K +$252K +325,109 +115%
E
18
Ergoteles
New York
$593K +$410K +529,300 New
SAM
19
Sectoral Asset Management
Quebec, Canada
$431K +$298K +385,000 New
Primecap Management
20
Primecap Management
California
$360K -$7.16K -9,240 -3%
FAM
21
Formidable Asset Management
Ohio
$309K +$214K +275,556 New
TI
22
Tidal Investments
Wisconsin
$309K +$214K +275,556 New
IC
23
Ikarian Capital
Texas
$199K -$232K -300,000 -33%
CHAM
24
Clear Harbor Asset Management
Connecticut
$186K +$107K +138,500 +589%
SCM
25
Silverarc Capital Management
Massachusetts
$175K -$61.5K -79,320 -34%
1
2 3

MREO Hedge Fund Activity: Q2 2022 in Review

64 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q2 2022, worth a combined $71.8M — down 28% from $99.6M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new MREO positions and 12 closed out — a net gain of 6 holders — while 13 added to existing stakes and 18 trimmed.

The largest buyer was Boxer Capital, opening a new position worth an estimated $1.74M. The largest seller was OrbiMed, cutting an estimated $5.85M.

  • 64 institutional investors held Mereo BioPharma (MREO) as of Q2 2022, up from 60 in Q1 2022.
  • Funds reported $71.8M of Mereo BioPharma stock for Q2 2022, down 28% quarter-over-quarter.
  • 18 funds opened new Mereo BioPharma positions in Q2 2022 and 12 closed out, a net change of +6 holders.
  • The largest Mereo BioPharma buyer in Q2 2022 was Boxer Capital, an estimated $1.74M added.
  • The largest Mereo BioPharma seller in Q2 2022 was OrbiMed, an estimated $5.85M sold.

Based on aggregated 13F filings for Q2 2022.